CING Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cingulate Inc (CING) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. The stock lacks positive trading signals, has weak financial performance, and no significant catalysts in the near term. While the FDA decision on May 31 could act as a potential catalyst, the current technical indicators and financials suggest holding off on investment until more clarity or positive signals emerge.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 25.299, and moving averages are converging, showing no clear trend. Key support is at 5.212, and resistance is at 6.465. The stock is trending sideways with no strong directional movement.
could act as a potential positive catalyst if approved.
Weak financial performance with declining EPS (-50.79% YoY) and negative net income (-$6.27M). Technical indicators suggest bearish or neutral momentum. No recent news or significant trading trends to support a bullish case.
In Q4 2025, revenue remained at $0 with no growth. Net income slightly improved by 0.67% YoY but remains negative at -$6.27M. EPS dropped significantly by -50.79% YoY to -0.93, reflecting poor profitability.
Roth Capital recently lowered the price target from $16 to $14 while maintaining a Buy rating. This reflects tempered optimism, likely tied to the FDA decision on May 31. No other recent analyst updates are available.
